Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon

November 2015

You'll hear cautious optimism about cardiovascular benefits with the SGLT2 inhibitor, Jardiance (empagliflozin).

Until now, metformin seemed to be the only diabetes med linked to a reduction in cardiovascular events in patients with type 2 diabetes.

But new evidence suggests that Jardiance also reduces CV risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote